{"disease":{"id":"pemphigoid-bullous","name":"pemphigoid bullous"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06148090","title":"Screening for Adrenal Insufficiency During Dermocorticoid Reduction in Bullous Pemphigoid (BP)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT01705795","title":"Anti-IL-5 Therapy in Bullous Pemphigoid (BP)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Insel Gruppe AG, University Hospital Bern","has_results":false},{"nct_id":"NCT03856840","title":"Cytokines in Blister Fluids of Bullous Pemphigoid (BP)","phase":"","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Mahmut Can Koska","has_results":false},{"nct_id":"NCT04465292","title":"The Effects of Tildrakizumab in Treatment of Bullous Pemphigoid","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":16,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT01559155","title":"Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid","phase":"","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nīmes","has_results":false},{"nct_id":"NCT02226146","title":"Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04499235","title":"A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Alkahest, Inc.","has_results":true}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}